MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
002038.SZ stock logo

002038.SZ

Beijing SL Pharmaceutical Co., Ltd.

$6.95
-0.23
 (-3.2%)
Exchange:  SHZ
Market Cap:  7.14B
Shares Outstanding:  1.027B
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  Mingbo Xu
Full Time Employees:  856
Address: 
Building 1, Bitongyuan
Beijing
100049
CN
Website:  https://www.slpharm.com.cn
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People’s Republic of China and internationally. The company’s finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People’s Republic of China.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202220232024
Revenue1,050,165.4241,018,358.696660,419.603
Gross Profit893,209.506829,551.126448,329.651
EBITDA257,168.491365,495.725180,587.235
Operating Income263,317.181477,869.983-119,603.351
Net Income234,404.161416,691.944-74,065.656

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202220232024
Total Assets5,875,839.8696,277,761.8455,979,019.318
Total Liabilities396,601.661467,724.343398,371.079
Total Stockholders Equity5,468,082.3275,800,616.1005,572,447.942
Total Debt037,593.2801,260
Cash and Cash Equivalents595,037.834683,831.097411,958.243

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202220232024
Operating Cash Flow389,820.900460,197.295225,487.183
Capital Expenditure-163,487.430-218,359.623-347,381.799
Free Cash Flow226,333.469241,837.676-121,894.616
Net Income234,404.161416,691.942-74,065.657
Net Change in Cash-253,213.98212,844.822-140,165.192

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2022Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)3,349,011.600Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)3,349,011.600Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)3,349,011.600Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)903,710.110Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)903,710.110Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)903,710.110Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)824,350.771Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)824,350.771Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)824,350.771Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)1,556,137.418Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,556,137.418Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,556,137.418Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.780Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.780Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.780Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
13.49
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
93.21
?Enterprise Value
 (TTM)
: 
7.443B  ?EV/FCF
 (TTM)
: 
-26.05
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0.25
?ROE
 (TTM)
: 
0.01  ?ROIC
 (TTM)
: 
0.01
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0
?P/B
 (TTM)
: 
1.37  ?Current Ratio
 (TTM)
: 
12.37

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate SZ Intrinsic Value

Common questions about 002038.SZ valuation

Is Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is 002038.SZ a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 002038.SZ trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is 002038.SZ’s P/E ratio?

You can see 002038.SZ’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for 002038.SZ?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is 002038.SZ a good long-term investment?

Whether 002038.SZ fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

002038.SZ

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-3.2
MARKETSnap

Trading Metrics:

Open: 7.61   Previous Close: 7.18
Day Low: 6.94   Day High: 7.61
Year Low: 5.47   Year High: 9.4
Price Avg 50: 6.78   Price Avg 200: 7.42
Volume: 52.953M   Average Volume: 60.149M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
Could not create stock discussion for SZ

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read